𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Carboplatin and ifosfamide in ovarian cancer phase II and III trials

✍ Scribed by E. Wiltshaw; T. J. Perren; I. D. Fryatt; P. R. Blake; P. Harper; M. Slevin

Publisher
Springer
Year
1990
Tongue
English
Weight
285 KB
Volume
26
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of carboplatin and etopos
Phase II trial of carboplatin and etoposide in metastatic breast cancer
✍ John Crown; Thomas Hakes; Bonnie Reichman; David Lebwohl; Theresa Gilewski; Anto πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 345 KB πŸ‘ 2 views

## Background: High-dose chemotherapy with hematopoietic support produces high rates of response in metastatic breast cancer. to facilitate new high-dose regimens there is a need to identify active agents with toxicity limited to hematopoietic suppression. cisplatin/etoposide is a highly active reg

FAU regulates carboplatin resistance in
FAU regulates carboplatin resistance in ovarian cancer
✍ Esther L. Moss; Mirna Mourtada-Maarabouni; Mark R. Pickard; Charles W. Redman; G πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 170 KB

## Abstract The development of chemotherapy resistance by cancer cells is complex, using different mechanisms and pathways. The gene __FAU__ (Finkel‐Biskis‐Reilly murine sarcoma virus (__F__BR‐MuSV)‐__a__ssociated __u__biquitously expressed gene) was identified through functional expression cloning